Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VRTX - Vertex Pharmaceuticals Incorpor
Market Cap 92.31B P/E 28.51 EPS this Y -97.80% Ern Qtrly Grth -
Income -489.9M Forward P/E 22.18 EPS next Y 5,443.70% 50D Avg Chg 4.00%
Sales 10.34B PEG 119.06 EPS past 5Y 27.36% 200D Avg Chg 12.00%
Dividend N/A Price/Book 5.97 EPS next 5Y 12.33% 52W High Chg -2.00%
Recommedations 2.20 Quick Ratio 2.10 Shares Outstanding 258.10M 52W Low Chg 32.00%
Insider Own 0.08% ROA 12.96% Shares Float 257.33M Beta 0.41
Inst Own 95.59% ROE -3.24% Shares Shorted/Prior 4.34M/4.42M Price 358.40
Gross Margin 53.65% Profit Margin -4.74% Avg. Volume 1,274,488 Target Price 512.20
Oper. Margin 35.34% Earnings Date Nov 4 Volume 2,166,599 Change 3.07%
Healthcare | Biotechnology | United States
About Vertex Pharmaceuticals Incorpor

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorpor News
12/21/24 Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
12/21/24 3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
12/21/24 My Top 10 Stocks to Buy for 2025
12/20/24 Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
12/20/24 Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
12/20/24 Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
12/20/24 VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
12/20/24 Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
12/19/24 S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat
12/19/24 Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug
12/19/24 Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’
12/19/24 Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
12/19/24 Accenture, Robinhood and Coinbase, Vertex: Market Minute
12/19/24 Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise.
12/19/24 Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic
12/19/24 Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
12/19/24 Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
12/19/24 Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
12/19/24 Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
12/19/24 2 Unstoppable Stocks to Buy and Hold for the Next Decade
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bozic Carmen EVP and CMO EVP and CMO Oct 03 Sell 345.28 5,651 1,951,177 46,254 10/05/23
Ambrose Kristen SVP & Chief Accounti.. SVP & Chief Accounting Officer May 30 Sell 329.82 289 95,318 6,838 06/01/23
Tatsis Ourania EVP, Chief Reg. & Qu.. EVP, Chief Reg. & Quality Off. Feb 24 Sell 288.27 354 102,048 56,805 02/28/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 24 Sell 287.89 5,034 1,449,238 56,556 02/28/23
Ambrose Kristen SVP & Chief Accounti.. SVP & Chief Accounting Officer Feb 24 Sell 288.52 1,207 348,244 7,303 02/28/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 24 Sell 288.52 4,238 1,222,748 32,038 02/28/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 22 Sell 294.14 2,401 706,230 66,304 02/24/23
Arbuckle Stuart A EVP, COO EVP, COO Feb 17 Sell 293.03 2,402 703,858 68,705 02/22/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 17 Sell 293.13 4,002 1,173,106 40,246 02/22/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 06 Sell 304.48 1,304 397,042 68,645 02/08/23
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Feb 06 Option 187.53 1,304 244,539 69,949 02/08/23
Kewalramani Reshma CEO & President CEO & President Jan 25 Sell 315.05 10,000 3,150,500 89,598 01/27/23
Lee Yuchun Director Director Jan 17 Sell 312.1 4,442 1,386,348 1,875 01/19/23
Lee Yuchun Director Director Jan 17 Option 72.14 4,442 320,446 2,317 01/19/23
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Oct 18 Sell 300.93 1,791 538,966 39,192 10/20/22
Kewalramani Reshma CEO & President CEO & President Aug 15 Sell 305.06 11,689 3,565,846 99,598 08/17/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 15 Option 155.57 6,571 1,022,250 67,451 08/17/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 15 Sell 303.05 22,173 6,719,528 45,278 08/17/22
Liu Joy SVP, General Counsel SVP, General Counsel Aug 15 Sell 303.14 3,747 1,135,866 9,605 08/17/22
Bhatia Sangeeta N. Director Director Aug 08 Sell 292.97 621 181,934 4,661 08/10/22
Liu Joy SVP, General Counsel SVP, General Counsel Aug 09 Sell 300.00 946 283,800 13,388 08/10/22
Tatsis Ourania EVP, Chief Reg. & Qu.. EVP, Chief Reg. & Quality Off. Aug 09 Sell 299.68 1,400 419,552 46,090 08/10/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 09 Option 155.57 1,926 299,628 66,686 08/10/22
Arbuckle Stuart A EVP, COO EVP, COO Aug 09 Sell 300.98 5,690 1,712,576 60,996 08/10/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Aug 08 Sell 292.8 1,304 381,811 36,077 08/10/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Aug 08 Option 187.53 1,304 244,539 37,381 08/10/22
Bhatia Sangeeta N. Director Director Jul 29 Sell 279.58 621 173,619 5,282 08/02/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Jul 19 Option 171.55 17,765 3,047,586 53,942 07/21/22
ALTSHULER DAVID EVP, Global Research.. EVP, Global Research and CSO Jul 19 Sell 288.18 17,865 5,148,336 36,077 07/21/22
Arbuckle Stuart A EVP, COO EVP, COO May 02 Sell 263.98 306 80,778 64,760 05/04/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies May 02 Sell 259.66 320 83,091 41,696 05/04/22
Bhatia Sangeeta N. Director Director May 02 Sell 259.81 737 191,480 5,903 05/04/22
WAGNER CHARLES F JR EVP & Chief Financia.. EVP & Chief Financial Officer May 02 Sell 259.61 343 89,046 42,730 05/04/22
Lee Yuchun Director Director Apr 18 Option 81.54 2,000 163,080 3,875 04/20/22
Lee Yuchun Director Director Apr 18 Sell 284.68 2,000 569,360 1,875 04/20/22
Lee Yuchun Director Director Apr 14 Option 81.54 2,000 163,080 3,875 04/18/22
Lee Yuchun Director Director Apr 14 Sell 289.45 2,000 578,900 1,875 04/18/22
LEIDEN JEFFREY M Executive Chairman Executive Chairman Apr 13 Sell 289.04 15,789 4,563,653 74,160 04/14/22
Lee Yuchun Director Director Apr 12 Option 81.54 4,000 326,160 3,875 04/14/22
Lee Yuchun Director Director Apr 12 Sell 284.86 4,000 1,139,440 1,875 04/14/22
Lee Yuchun Director Director Apr 08 Option 81.54 4,000 326,160 3,875 04/12/22
Lee Yuchun Director Director Apr 08 Sell 279.38 4,000 1,117,520 1,875 04/12/22
Bhatia Sangeeta N. Director Director Apr 08 Option 125.71 1,907 239,729 7,098 04/12/22
Bhatia Sangeeta N. Director Director Apr 08 Sell 280.2 1,907 534,341 5,191 04/12/22
MCGLYNN MARGARET G Director Director Apr 08 Option 127.54 5,000 637,700 6,099 04/12/22
MCGLYNN MARGARET G Director Director Apr 08 Sell 280.84 5,000 1,404,200 1,099 04/12/22
Lee Yuchun Director Director Apr 06 Option 81.54 4,000 326,160 3,875 04/08/22
Lee Yuchun Director Director Apr 06 Sell 273.12 4,000 1,092,480 1,875 04/08/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Apr 07 Sell 276.37 561 155,044 42,782 04/08/22
Sanna Bastiano EVP, Cell & Genetic.. EVP, Cell & Genetic Therapies Apr 04 Sell 270.25 3,725 1,006,681 43,343 04/06/22